Showing 5591-5600 of 8729 results for "".
- Povorcitinib Produces Lasting Results in HShttps://practicaldermatology.com/news/povorcitinib-produces-lasting-results-in-hs/2461557/Longer-term treatment with povorcitinib 75 mg resulted in sustained and durable efficacy across all treatment arms in a phase 2 study of hidradenitis suppurativa (HS) patients. Povorcitinib is an oral JAK1 inhibitor. These data were presented as an oral presentation at th
- DermTech Melanoma Test Recommended for Coverage by the Veterans Health Administrationhttps://practicaldermatology.com/news/dermtech-melanoma-test-recommended-for-coverage-by-the-veterans-health-administration/2461554/The U.S. General Services Administration has recommended DermTech‘s foundational assay included in the DermTech Melanoma Test (DMT) for coverage by the Veterans Health Administration (VHA), according to a company news release. This coverage recommendation makes the foundational as
- Medical Groups Offer Updated Guidance on Hand Hygiene in Healthcare Settingshttps://practicaldermatology.com/news/groups-offer-updated-guidance-on-hand-hygiene-in-healthcare-settings/2461551/Five medical organizations are recommending updated best practices for hand hygiene to protect patients and staff in healthcare settings. The new recommendations emphasize the importance of healthy skin and nails and easy access to alcohol-based hand sanitizers. Strategi
- Study: Six Percent of Children Have Eczema Symptoms Worldwidehttps://practicaldermatology.com/news/study-six-percent-of-children-have-eczema-symptoms-worldwide/2461550/About 6% of children and adolescents have some form of eczema, according to New research published in Clinical & Experimental Allergy. In addition, 0.6% of children and 1.1% of adolescents across the g
- Meet TargetCool, CoolHealth's Solution to Post-Procedure Pain, Bruisinghttps://practicaldermatology.com/news/meet-targetcool-coolhealths-solution-to-post-procedure-pain-bruising/2461549/CoolHealth is entering the U.S. market with TargetCool. Leveraging tuneable cooling technology, TargetCool rapidly cools the skin, allowing providers to specifically set a “target” skin temperature down to the exact degree and
- Cutera Launches Rewards Program for High-Volume AviClear Usershttps://practicaldermatology.com/news/cutera-launches-rewards-program-for-high-volume-aviclear-users/2461548/Practices in the United States and Canada using AviClear will now have access to more perks. Cutera announced that it will be launching a rewards program for AviClear practices designed to reinforce a partnership approach with practices with improved profitability, e
- MTX Use May Up Risk for Three Types of Skin Cancerhttps://practicaldermatology.com/news/mtx-use-may-up-skin-cancer-risk/2461546/Methotrexate (MTX) may increase risk for three types of skin cancer, according to a new study out of University of Gothenburg. Patients receiving the drug include those with moderate to severe psoriasis; but in this particular patient group, a risk increase was only observed for basal c
- Murad, Active Minds Join Forces to Help Young Adults Stress Lesshttps://practicaldermatology.com/news/murad-active-minds-join-forces-to-help-young-adults-stress-less/2461543/Murad is partnering with Active Minds, a nonprofit supporting mental health awareness and education for young adults. In 2003, Dr. Murad coined the term 'cultural stress', the day-to-day stress of modern living as a major factor contributing to the chronic exhau
- Escient Pharmaceuticals Receives FDA IND Clearance to Start Phase 1 Study of EP262https://practicaldermatology.com/news/escient-pharmaceuticals-receives-fda-ind-clearance-to-start-phase-1-study-of-ep262/2461542/The FDA has cleared Escient Pharmaceuticals’ investigational new drug (IND) application for EP262. The clearance allows the Escient to initiate a Phase 1 first-in-human study for the company’s second drug candidate to be advanced into clinical development. EP262 is a first-i
- Avero Diagnostics Launches Test for Early-Stage Melanoma Progressionhttps://practicaldermatology.com/news/avero-diagnostics-launches-test-for-early-stage-melanoma-progression/2461541/Avero Diagnostics announced the US launch of AMBLor, a laboratory test for the identification of early-stage melanomas at low risk of progression. AMBLor technology identifies the presence of two prognostic biomarker proteins, AMBRA1 and loricrin, in the skin overlying the tumor, a